Metixene (hydrochloride hydrate)

Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride hydrate potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used for the research of parkinsonian[1][2][3].

Product Specifications

CAS Number

[7081-40-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Metixene_hydrochloride_hydrate.html

Purity

99.92

Solubility

DMSO : 77.5 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic)

Smiles

CN1CC(CCC1)CC2C3=C(C=CC=C3)SC4=C2C=CC=C4.Cl.O

Molecular Formula

C20H26ClNOS

Molecular Weight

363.94

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]J. Hagenah, et al. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence. , 106 (3-4), 301–307. doi:10.1007/s007020050159 |[2]S L Levin, et al. Dualism in the effect of cholinolytics upon the human parotid gland deprived of parasympathetic control. Int J Clin Pharmacol Res. 1986;6 (5) :429-39.